Last month, the FTC voted unanimously to examine rising list prices of insulin, but also to probe possible anti-competitive practices by PBMs. Proof of the establishment of anti-competitive practices - such as rebate walls - would likely lead to legal action being taken against PBMs.
Subscribe to:
Post Comments (Atom)
< + > Healthcare IT Failures – Healthcare IT Today Podcast Episode 195
For the 195th episode of the Healthcare IT Today Podcast , we are taking a look at healthcare IT failures! We kick this episode off by debat...
No comments:
Post a Comment